$MEDI conducting 2 research studies Big news for KetamineOne Capital Limited ( $MEDI.N $KONEF)!
Yesterday the mental health clinics and treatment company announced that they will launch a study of PTSD patients who are participating in therapy at their IRP Health clinics.
Additionally, $MEDI is also conducting a pilot study aimed at collecting objective biometric data and psychiatric measures of efficacy for depressed patients who are receiving IV ketamine infusion therapy at their clinics.
Both of these studies will be conducted in multiple Ketamine One clinics across Canada and the USA and are expected to begin in November.
It is great to see that $MEDI is not only adding to the scientific community but also continuing to validate their own treatments' efficacy.
$MEDI @ $0.58, MC $69.69 M
For more info on the details of both studies read here:
https://www.globenewswire.com/news-release/2021/10/14/2313950/0/en/Ketamine-One-Launching-Two-Inaugural-Research-Studies.html